24 results on '"Yousefi, Bahman"'
Search Results
2. Natural products and the balancing act of autophagy-dependent/independent ferroptosis in cancer therapy.
- Author
-
Rahimipour Anaraki, Shiva, Farzami, Payam, Hosseini Nasab, Seyed Soheil, Kousari, Ali, Fazlollahpour Naghibi, Andarz, Shariat Zadeh, Mahdieh, Barati, Reza, Taha, Seyed Reza, Karimian, Ansar, Nabi-Afjadi, Mohsen, and Yousefi, Bahman
- Subjects
NATURAL products ,CANCER treatment ,GLUTATHIONE peroxidase ,BCL genes ,MOLECULAR pathology ,REACTIVE oxygen species ,CELL death - Abstract
The control of biological cell death is essential for the body's appropriate growth. The resistance of cells to the apoptotic process presents a new difficulty in the treatment of cancer. To combat cancer cells, researchers are working to find new apoptotic pathways and components to activate. One of the processes of regulated cell death (RCD) is referred to as ferroptosis marked by a decline in the activity of lipid glutathione peroxidase 4 (GPX4) after the buildup of reactive oxygen species (ROS). Since lipid peroxidation is a crucial component of ferroptosis and is required for its start, numerous medicines have been studied, particularly for the treatment of cancer. In this context, autophagy is an additional form of RCD that can govern ferroptosis through shared signaling pathways/factors involved in both mechanisms. In this review, we will explore the molecular mechanisms underlying ferroptosis and its association with autophagy, to gain fresh insights into their interplay in cancer advancement, and the potential of natural products for its treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Applications of engineered exosomes in drugging noncoding RNAs for cancer therapy.
- Author
-
Alemi, Forough, Sadeghsoltani, Fatemeh, Fattah, Khashayar, Hassanpour, Parisa, Malakoti, Faezeh, Kardeh, Sina, Izadpanah, Melika, de Campos Zuccari, Debora Aparecida Pires, Yousefi, Bahman, and Majidinia, Maryam
- Subjects
NON-coding RNA ,EXOSOMES ,CANCER treatment ,CIRCULAR RNA ,CANCER prevention ,CANCER invasiveness - Abstract
Noncoding RNAs (ncRNAs) are engaged in key cell biological and pathological events, and their expression alteration is connected to cancer progression both directly and indirectly. A huge number of studies have mentioned the significant role of ncRNAs in cancer prevention and therapy that make them an interesting subject for cancer therapy. However, there are several limitations, including delivery, uptake, and short half‐life, in the application of ncRNAs in cancer treatment. Exosomes are introduced as promising options for the delivery of ncRNAs to the target cells. In this review, we will briefly discuss the application and barriers of ncRNAs. After that we will focus on exosome‐based ncRNAs delivery and their advantages as well as the latest achievements in drugging ncRNAs with exosomes. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
4. Targeting long non coding RNA by natural products: Implications for cancer therapy.
- Author
-
Homayoonfal, Mina, Asemi, Zatollah, and Yousefi, Bahman
- Subjects
NATURAL products ,CANCER treatment ,LINCRNA ,CANCER cell growth ,RNA ,NON-coding RNA ,TUMOR suppressor proteins - Abstract
In spite of achieving substantial progress in its therapeutic strategies, cancer-associated prevalence and mortality are persistently rising globally. However, most malignant cancers either cannot be adequately diagnosed at the primary phase or resist against multiple treatments such as chemotherapy, surgery, radiotherapy as well as targeting therapy. In recent decades, overwhelming evidences have provided more convincing words on the undeniable roles of long non-coding RNAs (lncRNAs) in incidence and development of various cancer types. Recently, phytochemical and nutraceutical compounds have received a great deal of attention due to their inhibitory and stimulatory effects on oncogenic and tumor suppressor lncRNAs respectively that finally may lead to attenuate various processes of cancer cells such as growth, proliferation, metastasis and invasion. Therefore, application of phytochemicals with anticancer characteristics can be considered as an innovative approach for treating cancer and increasing the sensitivity of cancer cells to standard prevailing therapies. The purpose of this review was to investigate the effect of various phytochemicals on regulation of lncRNAs in different human cancer and evaluate their capabilities for cancer treatment and prevention. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
5. Interactions of melatonin with various signaling pathways: implications for cancer therapy.
- Author
-
Mihanfar, Ainaz, Yousefi, Bahman, Azizzadeh, Bita, and Majidinia, Maryam
- Subjects
- *
CELLULAR signal transduction , *CANCER treatment , *MELATONIN , *CIRCADIAN rhythms , *CANCER invasiveness - Abstract
Melatonin is a neuro-hormone with conserved roles in evolution. Initially synthetized as an antioxidant molecule, it has gained prominence as a key molecule in the regulation of the circadian rhythm. Melatonin exerts its effect by binding to cytoplasmic and intra-nuclear receptors, and is able to regulate the expression of key mediators of different signaling pathways. This ability has led scholars to investigate the role of melatonin in reversing the process of carcinogenesis, a process in which many signaling pathways are involved, and regulating these pathways may be of clinical significance. In this review, the role of melatonin in regulating multiple signaling pathways with important roles in cancer progression is discussed, and evidence regarding the beneficence of targeting malignancies with this approach is presented. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
6. The importance of co‐delivery of nanoparticle‐siRNA and anticancer agents in cancer therapy.
- Author
-
Khelghati, Nafiseh, Soleimanpour Mokhtarvand, Jafar, Mir, Mostafa, Alemi, Forough, Asemi, Zatollah, Sadeghpour, Alireza, Maleki, Masomeh, Samadi Kafil, Hossein, Jadidi‐niaragh, Farhad, Majidinia, Maryam, and Yousefi, Bahman
- Subjects
ANTINEOPLASTIC agents ,CANCER treatment ,MULTIDRUG resistance ,CELL cycle ,SMALL interfering RNA - Abstract
According to global statistics, cancer is the second leading cause of death worldwide. Because of the heterogeneity of cancer, single‐drug therapy has many limitations due to low efficacy. Therefore, combination therapy with two or more therapeutic agents is being arisen. One of the most important approaches in cancer therapy is the shot down of key genes involved in apoptotic processes and cell cycle. In this regard, siRNA is a good candidate, a highly attractive method to suppressing tumor growth and invasion. Combination therapy with siRNAs and chemotherapeutic agents can overcome the multidrug resistance and increase apoptosis. The efficient delivery of siRNA to the target cell/tissue/organ has been a challenge. To overcome these challenges, the presence of suitable delivery systems by using nanoparticles is interesting. In this review, we discuss the current challenges for successful RNA interference. Also, we suggested proper a strategy for delivering siRNA that can be useful in targeting therapy. Finally, the combination of a variety of anticancer drugs and siRNA through acceptable delivery systems and their effects on cell cycle and apoptosis will be evaluated. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Targeting vasculogenic mimicry by phytochemicals: A potential opportunity for cancer therapy.
- Author
-
Haiaty, Sanya, Rashidi, Mohammad‐Reza, Akbarzadeh, Maryam, Maroufi, Nazila F., Yousefi, Bahman, and Nouri, Mohammad
- Subjects
VASCULOGENIC mimicry ,PHYTOCHEMICALS ,PROANTHOCYANIDINS ,CANCER treatment ,GRAPE seeds ,CANCER relapse ,METASTASIS - Abstract
Vasculogenic mimicry (VM) is regarded as a process where very aggressive cancer cells generate vascular‐like patterns without the presence of endothelial cells. It is considered as the main mark of malignant cancer and has pivotal role in cancer metastasis and progression in various types of cancers. On the other hand, resistance to the antiangiogenesis therapies leads to the cancer recurrence. Therefore, development of novel chemotherapies and their combinations is urgently needed for abolition of VM structures and also for better tumor therapy. Hence, identifying compounds that target VM structures might be superior therapeutic factors for cancers treatment and controlling the recurrence and metastasis. In recent times, naturally occurring compounds, especially phytochemicals have obtained great attention due to their safe properties. Phytochemicals are also capable of targeting VM structure and also their main signaling pathways. Consequently, in this review article, we illustrated key signaling pathways in VM, and the phytochemicals that affect these structures including curcumin, genistein, lycorine, luteolin, columbamine, triptolide, Paris polyphylla, dehydroeffusol, jatrorrhizine hydrochloride, grape seed proanthocyanidins, resveratrol, isoxanthohumol, dehydrocurvularine, galiellalactone, oxacyclododecindione, brucine, honokiol, ginsenoside Rg3, and norcantharidin. The recognition of these phytochemicals and their safety profile may lead to new therapeutic agents' development for VM elimination in different types of tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
8. Importance of probiotics in the prevention and treatment of colorectal cancer.
- Author
-
Eslami, Majid, Yousefi, Bahman, Kokhaei, Parviz, Hemati, Maral, Nejad, Zahra Rasouli, Arabkari, Vahid, and Namdar, Afshin
- Subjects
- *
PROBIOTICS , *COLORECTAL cancer , *GUT microbiome , *CANCER treatment , *AMINO acid synthesis , *PATHOGENIC microorganisms - Abstract
Colorectal cancer (CRC) remains one of the most common and deadly cancers. Intestinal gut microflora is important to maintain and contributes to several intestinal functions, including the development of the mucosal immune system, absorption of complex macromolecules, synthesis of amino acids/vitamins and the protection against pathogenic microorganisms. It is well known that the gut microbiota changes or dysbiosis may have an essential impact in the initiation and promotion of chronic inflammatory pathways and also have a profound different genetic and epigenetic alterations leading to dysplasia, clonal expansion, and malignant transformation. Probiotic bacteria has antitumor activity with various mechanisms such as nonspecific physiological and immunological mechanisms. This review evaluates the effects of microbiota and probiotics in clinical trials, in vitro and animal model studies that have explored how probiotic against cancer development and also discusses the possible immunomodulatory mechanisms. Several mechanisms alteration of the intestinal microflora; inactivation of cancerogenic compounds; competition with putrefactive and pathogenic microbiota; improvement of the host's immune response; antiproliferative effects via regulation of apoptosis and cell differentiation; fermentation of undigested food; inhibition of tyrosine kinase; reduces the enteropathogenic complications before and after colon cancer surgery and improve diarrhea and it's have been able to create the integrity of gut mucosal and have stimulatory effects on the systemic immune system and prevent the CRC metastasis. Research in clinical trials encouraging findings that support a role of probiotics in CRC prevention and improve the safety and effectiveness of cancer therapy even though additional clinical research is still necessary. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
9. Is it true that gut microbiota is considered as panacea in cancer therapy?
- Author
-
Salek Farrokhi, Amir, Darabi, Narges, Yousefi, Bahman, Askandar, Rafee Habib, Shariati, Mansoreh, and Eslami, Majid
- Subjects
PROGRAMMED cell death 1 receptors ,CANCER treatment ,CYTOTOXIC T cells ,BACTEROIDES fragilis ,CANCER chemotherapy ,GUT microbiome ,CANCER immunotherapy - Abstract
Recent studies demonstrated that a combination of the gut microbiome has the vital effect on the efficacy of anticancer immune therapies. Regulatory effects of microbiota have been shown in different types of cancer therapies such as chemotherapy and immunotherapy. Immune‐checkpoint‐blocked therapies are the recent efficient cancer immunotherapy strategies. The target of immune‐checkpoint blocking is cytotoxic T lymphocyte protein‐4 (CTLA‐4) or blockade of programmed death‐1 (PD‐1) protein and its ligand programmed death ligand 1 (PD‐L1) that they have been considered as cancer immunotherapy in recent years. In the latest studies, it have been demonstrated that several gut bacteria such as Akkermansia muciniphila, Bifidobacterium spp., Faecalibacterium spp., and Bacteroides fragilis have the regulatory effects on PD‐1, PD‐L1, and CTLA‐4 blocked anticancer therapy outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. S1PR1 as a Novel Promising Therapeutic Target in Cancer Therapy.
- Author
-
Rostami, Narges, Nikkhoo, Afshin, Ajjoolabady, Amir, Azizi, Gholamreza, Hojjat-Farsangi, Mohammad, Ghalamfarsa, Ghasem, Yousefi, Bahman, Yousefi, Mehdi, and Jadidi-Niaragh, Farhad
- Subjects
CYCLIC adenylic acid ,CELL receptors ,CANCER treatment ,IMMUNOLOGICAL tolerance ,HEMATOLOGIC malignancies ,INTERLEUKIN-6 - Abstract
Sphingosine-1-phosphate (S1P) can regulate several physiological and pathological processes. S1P signaling via its cell surface receptor S1PR1 has been shown to enhance tumorigenesis and stimulate growth, expansion, angiogenesis, metastasis, and survival of cancer cells. S1PR1-mediated tumorigenesis is supported and amplified by activation of downstream effectors including STAT3, interleukin-6, and NF-κB networks. S1PR1 signaling can also trigger various other signaling pathways involved in carcinogenesis including activation of PI3K/AKT, MAPK/ERK1/2, Rac, and PKC/Ca, as well as suppression of cyclic adenosine monophosphate (cAMP). It also induces immunological tolerance in the tumor microenvironment, while the immunosuppressive function of S1PR1 can also lead to the generation of pre-metastatic niches. Some tumor cells upregulate S1PR1 signaling pathways, which leads to drug resistant cancer cells, mainly through activation of STAT3. This signaling pathway is also implicated in some inflammatory conditions leading to the instigation of inflammation-driven cancers. Furthermore, it can also increase survival via induction of anti-apoptotic pathways, for instance, in breast cancer cells. Therefore, S1PR1 and its signaling pathways can be considered as potential anti-tumor therapeutic targets, alone or in combination therapies. Given the oncogenic nature of S1PR1 and its distribution in a variety of cancer cell types along with its targeting advantages over other molecules of this family, S1PR1 should be considered a favorable target in therapeutic approaches to cancer. This review describes the role of S1PR1 in cancer development and progression, specifically addressing breast cancer, glioma, and hematopoietic malignancies. We also discuss the potential use of S1P signaling modulators as therapeutic targets in cancer therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
11. CRISPR/Cas9 technology as a potent molecular tool for gene therapy.
- Author
-
Karimian, Ansar, Azizian, Khalil, Parsian, Hadi, Rafieian, Sona, Shafiei‐Irannejad, Vahid, Kheyrollah, Maryam, Yousefi, Mehdi, Majidinia, Maryam, and Yousefi, Bahman
- Subjects
GENE therapy ,NANOTECHNOLOGY ,GENOME editing ,ZINC-finger proteins ,CANCER treatment ,NUCLEASES - Abstract
Clustered regularly interspaced short palindromic repeats/CRISPR‐associated nuclease 9 (CRISPR‐Cas9) is an RNA‐guided gene editing tool which offers several advantageous characteristics in comparison with the conventional methods (e.g., zinc finger nucleases and transcription activator‐like effector nucleases) such as cost‐effectiveness, flexibility, and being easy‐to‐use. Despite some limitations such as efficient delivery and safety, CRISPR‐Cas9 is still the most convenient tool for gene editing purposes. Due to the potential capability of the CRISPR‐Cas9 system in genome editing and correction of casual mutations, it can be considered as a possible therapeutic system in the treatment of disorders associated with the genome mutations and in particular cancer treatment. In this review, we will discuss CRISPR‐Cas‐based gene editing along with its classifications and mechanism of action. Furthermore, the therapeutic application of the CRISPR‐Cas9 system in mutational disorders, delivery systems, as well as its advantages and limitations with a special emphasis on cancer treatment will be discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
12. Combination of nanotechnology with vascular targeting agents for effective cancer therapy.
- Author
-
Jahanban‐Esfahlan, Rana, Seidi, Khaled, Banimohamad‐Shotorbani, Behnaz, Jahanban‐Esfahlan, Ali, and Yousefi, Bahman
- Subjects
CANCER treatment ,NANOTECHNOLOGY ,ENDOTHELIAL cells ,CANCER cells ,NANOSTRUCTURES ,PROTEIN-tyrosine kinases - Abstract
As a young science, nanotechnology promptly integrated into the current oncology practice. Accordingly, various nanostructure particles were developed to reduce drug toxicity and allow the targeted delivery of various diagnostic and therapeutic compounds to the cancer cells. New sophisticated nanosystems constantly emerge to improve the performance of current anticancer modalities. Targeting tumor vasculature is an attractive strategy to fight cancer. Though the idea was swiftly furthered from basic science to the clinic, targeting tumor vasculature hada limited potential in patients, where tumors relapse due to the development ofmultiple drug resistance and metastasis. The aim of this review is to discuss the advantages of nanosystem incorporation with various vascular targeting agents, including (i) endogen anti-angiogenic agents; (ii) inhibitors of angiogenesis-related growth factors; (iii) inhibitors of tyrosine kinase receptors; (iv) inhibitors of angiogenesisrelated signaling pathways; (v) inhibitors of tumor endothelial cell-associated markers; and (vi) tumor vascular disrupting agents. We also review the efficacy of nanostructures as natural vascular targeting agents. The efficacy of each approach in cancer therapy is further discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2018
- Full Text
- View/download PDF
13. New insights into antidiabetic drugs: Possible applications in cancer treatment.
- Author
-
Shafiei‐Irannejad, Vahid, Samadi, Nasser, Salehi, Roya, Yousefi, Bahman, and Zarghami, Nosratollah
- Subjects
PHYSIOLOGICAL effects of hypoglycemic agents ,DRUG efficacy ,TREATMENT of diabetes ,CANCER treatment ,DISEASE management - Abstract
Globally at 2014, it was estimated that there was 347 million people with diabetes in which 90 percent of them were diagnosed with type 2 diabetes mellitus (T2 DM). Although the association between diabetes mellitus and cancer risk was found about 100 years ago, the issue is not still clear. Many studies especially cohort and case-control studies have suggested a higher risk of cancer in patients with diabetes mainly in those with type 2 diabetes. Insulin concentration is high in these patients, and due to its mitogenic effects, it may be a possible hypotheses for higher risk of cancer in diabetic patients. Therefore, antidiabetic drugs, which are involved in insulin secretion and sensitivity, may have beneficial effects in cancer treatment. Several groups of drugs with different mechanisms of action, mostly prescribed orally, are used for the treatment of type 2 diabetes mellitus including, insulin sensitizers (thiazolidinediones), insulin secretagogues (sulfonylureas), and biguanides. In this review, the possible effects of antidiabetic drugs (biguanides, thiazolidinediones, and sulfonylureas) and some of their mechanisms for overcoming cancer will be discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
14. Melatonin: A pleiotropic molecule that modulates DNA damage response and repair pathways.
- Author
-
Majidinia, Maryam, Sadeghpour, Alireza, Mehrzadi, Saeed, Reiter, Russel J., Khatami, Nasrin, and Yousefi, Bahman
- Subjects
PHYSIOLOGICAL effects of melatonin ,DNA damage -- Risk factors ,CANCER treatment ,GENOMES ,DNA repair ,NUCLEOTIDE sequence ,GENETICS - Abstract
DNA repair is responsible for maintaining the integrity of the genome. Perturbations in the DNA repair pathways have been identified in several human cancers. Thus, compounds targeting DNA damage response ( DDR) hold great promise in cancer therapy. A great deal of effort, in pursuit of new anticancer drugs, has been devoted to understanding the basic mechanisms and functions of the cellular DNA repair machinery. Melatonin, a widely produced indoleamine in all organisms, is associated with a reduced risk of cancer and has multiple regulatory roles on the different aspects of the DDR and DNA repair. Herein, we have mainly discussed how defective components in different DNA repair machineries, including homologous recombination ( HR), nonhomologous end-joining ( NHEJ), base excision repair ( BER), nucleotide excision repair ( NER), and finally DNA mismatch repair ( MMR), can contribute to the risk of cancer. Melatonin biosynthesis, mode of action, and antioxidant effects are reviewed along with the means by which the indoleamine regulates DDR at the transduction, mediation, and functional levels. Finally, we summarize recent studies that illustrate how melatonin can be combined with DNA-damaging agents to improve their efficacy in cancer therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
15. DNA damage response regulation by microRNAs as a therapeutic target in cancer.
- Author
-
Majidinia, Maryam and Yousefi, Bahman
- Subjects
- *
DNA damage , *CANCER risk factors , *MICRORNA , *CANCER cells , *ANTINEOPLASTIC agents , *DNA repair , *CANCER treatment - Abstract
The inability of cancer cells in taking care of DNA damages can lead to cancer development and/or progression. Due to the essential role of DNA repair in maintaining genomic stability, tightly controlled regulatory mechanism are required for these processes. Recent studies have shown a myriad of interactions among DNA damage response (DDR) components and miRNAs. While DDR modulates miRNA expression in transcriptional and post-transcriptional levels and affects miRNA degradation, miRNAs in turn, directly modulate the expression of multiple proteins in the DDR pathways, or indirectly fine-tune the expression of such proteins. A better understanding of DDR-miRNA interactions can facilitate the development of new anticancer agents targeting miRNAs involved in the DNA repair process. In this review, we provide a brief introduction about miRNA biogenesis and functions, DDR pathways, and recent findings about DDR-microRNA interactions. Finally, the therapeutic importance of miRNAs in modulation of DDR/DNA repair mechanisms will be discussed. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
16. Long non-coding RNAs in cancer drug resistance development.
- Author
-
Majidinia, Maryam and Yousefi, Bahman
- Subjects
- *
DRUG resistance in cancer cells , *CANCER treatment , *NON-coding RNA , *DNA repair , *DRUG development , *DRUG metabolism , *GENETIC transcription - Abstract
The presence or emergence of chemoresistance in tumor cells is a major burden in cancer therapy. While drug resistance is a multifactorial phenomenon arising from altered membrane transport of drugs, altered drug metabolism, altered DNA repair, reduced apoptosis rate and alterations of drug metabolism, it can also be linked to genetic and epigenetic factors. Long non-coding RNAs (lncRNAs) have important regulatory roles in many aspects of genome function including gene transcription, splicing, and epigenetics as well as biological processes involved in cell cycle, cell differentiation, development, and pluripotency. As such, it may not be surprising that some lncRNAs have been recently linked to carcinogenesis and drug resistance/sensitivity. Research is accelerating to decipher the exact molecular mechanism of lncRNA-regulated drug resistance and its therapeutic implications. In this article, we will review the structure, biogenesis, and mode of action of lncRNAs. Then, the involvement of lncRNAs in drug resistance will be discussed in detail. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
17. Effects of chitosan and oligochitosans on the phosphatidylinositol 3-kinase-AKT pathway in cancer therapy.
- Author
-
Amirani, Elaheh, Hallajzadeh, Jamal, Asemi, Zatollah, Mansournia, Mohammad Ali, and Yousefi, Bahman
- Subjects
- *
BIOPOLYMERS , *CANCER treatment , *PHOSPHATIDYLINOSITOL 3-kinases , *KINASE regulation , *CHITOSAN , *DNA - Abstract
Phosphatidylinositol 3-kinase (PI3K)-AKT pathway is one of the most important kinase signaling networks in the context of cancer development and treatment. Aberrant activation of AKT, the central mediator of this pathway, has been implicated in numerous malignancies including endometrial, hepatocellular, breast, colorectal, prostate, and, cervical cancer. Thus regulation and blockage of this kinase and its key target nodes is an attractive approach in cancer therapy and diverse efforts have been done to achieve this aim. Chitosan is a carbohydrate with multiple interesting applications in cancer diagnosis and treatment strategies. This bioactive polymer and its derivative oligomers commonly used in drug/DNA delivery methods due to their functional properties which improve efficiency of delivery systems. Further, these compounds exert anti-tumor roles through the stimulation of apoptosis, immune enhancing potency, anti-oxidative features and anti-angiogenic roles. Due to the importance of PI3K-AKT signaling in cancer targeting and treatment resistance, this review discusses the involvement of chitosan, oligochitosaccharides and carriers based on these chemicals in the regulation of this pathway in different tumors. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
18. The crosstalk between Wnt/β-catenin signaling pathway with DNA damage response and oxidative stress: Implications in cancer therapy.
- Author
-
Karimaian, Ansar, Majidinia, Maryam, Bannazadeh Baghi, Hossein, and Yousefi, Bahman
- Subjects
- *
CANCER treatment , *DNA damage , *CROSSTALK , *WNT signal transduction , *OXIDATIVE stress , *DNA repair - Abstract
DNA repair is essential for maintaining genomic integrity in cells. The dependence of cancer cell survival on proper DNA repair provides an opportunity to treat defective tumors by DNA damaging agents. Not only Wnt signaling has important functions in controlling gene expression, as well as cell polarity, adhesion and behavior, it also highly interacts with DNA damage response (DDR) in different levels. Furthermore, oxidative stress, which is responsible for majority of DNA lesions, affects Wnt signaling in different ways. A better understanding of the cross-talk between these pathways and events could provide strategies for treatment of cancer cells with deficient DNA repair capacity. As such, we will give a brief overview of the importance of the DNA repair machinery, signaling mechanisms of Wnt/β-catenin pathway, and DDR. We will further review the interactions between Wnt signaling and DDR, and the impact of oxidative stress on Wnt signaling. Finally, Wnt signaling is discussed as a potential treatment strategy for cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
19. mTOR pathway and DNA damage response: A therapeutic strategy in cancer therapy.
- Author
-
Danesh Pazhooh, Romina, Rahnamay Farnood, Parnia, Asemi, Zatollah, Mirsafaei, Liaosadat, Yousefi, Bahman, and Mirzaei, Hamed
- Subjects
- *
DNA repair , *DNA damage , *CANCER treatment , *CELL survival , *CARRIER proteins , *MTOR inhibitors - Abstract
[Display omitted] • The mammalian target of rapamycin (mTOR) is a conserved serine/threonine kinase. • DDR maintains genomic stability and provides an opportunity for treating tumors. • This paper discusses the involvement of the mTOR signaling pathway and its regulators in cancer development. The mammalian target of rapamycin (mTOR) is a conserved serine/threonine-protein kinase, comprising two subunit protein complexes: mTORC1 and mTORC2. In response to insult and cancer, the mTOR pathway plays a crucial role in regulating growth, metabolism, cell survival, and protein synthesis. Key subunits of mTORC1/2 catalyze the phosphorylation of various molecules, including eukaryotic translation initiation factor 4E binding protein 1 (4E-BP1), ribosomal protein S6 kinase β-1 (S6K1). The DNA damage response (DDR) maintains genomic stability and provides an opportunity for treating tumors with defects caused by DNA damaging agents. Many mTOR inhibitors are utilized for the treatment of cancers. However, several clinical trials are still assessing the efficacy of mTOR inhibitors. This paper discusses the role of the mTOR signaling pathway and its regulators in developing cancer. In the following, we will review the interaction between DDR and mTOR signaling and the innovative therapies applied in preclinical and clinical trials for treating cancers. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
20. DNA damage response and repair in pancreatic cancer development and therapy.
- Author
-
Rahnamay Farnood, Parnia, Danesh Pazhooh, Romina, Asemi, Zatollah, and Yousefi, Bahman
- Subjects
- *
DNA repair , *PANCREATIC cancer , *CANCER treatment , *CANCER chemotherapy , *SURVIVAL rate , *PROGNOSIS , *DNA damage , *CREUTZFELDT-Jakob disease - Abstract
• According to the severity of the damage, DDR pathways respond appropriately to lesions. • Novel agents are being utilized to improve the response of many cancers to chemotherapy and radiotherapy. • We briefly reviewed DDR processes and their components in the progression, prognosis, and treatment of PC. Pancreatic cancer (PC) is among fatal malignancies, with a dismal prognosis and a low survival rate of 5–10%. In both sporadic and inherited PC, gene alterations, such as BRCA1/2, PALB2, and ATM, can occur frequently. Currently, surgery, chemo- and radio-therapy are the most common therapeutic strategies for treating this cancer. DNA damage response (DDR) establishes multiple pathways that eliminate DNA damage sites to maintain genomic integrity. Various types of cancers and age-related diseases are associated with DDR machinery defects. According to the severity of the damage, DDR pathways respond appropriately to lesions through repairing damage, arresting the cell cycle, or apoptosis. Recently, novel agents, particularly those targeting DDR pathways, are being utilized to improve the response of many cancers to chemotherapy and radiotherapy. In this paper, we briefly reviewed DDR processes and their components, including DDR sensors, DDR mediators, and DDR transducers in the progression, prognosis, and treatment of PC. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
21. DNA damage response and repair in osteosarcoma: Defects, regulation and therapeutic implications.
- Author
-
Sadoughi, Fatemeh, Maleki Dana, Parisa, Asemi, Zatollah, and Yousefi, Bahman
- Subjects
- *
DNA repair , *DNA damage , *OSTEOSARCOMA , *PROGNOSIS , *CANCER treatment , *SURVIVAL analysis (Biometry) - Abstract
• Osteosarcoma (OS) is the most common primary with a survival rate of 20 % in its advanced stages. • These conclusions are not completely reliable because of the lack of in vivo and human studies on the most of the discussed DDR ingredients. • We tried to gather the evidence on the role of DDR in osteosarcoma's progression, prognosis, and treatment. Osteosarcoma (OS) is the most common primary bone malignancy in children and adolescents which has the survival rate of 20% in its advanced stages. Osteosarcomas are mostly resistance to our common treatments. DNA damage response (DDR) is a specialized multistep process containing abundant proteins which are necessary for the survival of any cell and organism. DDR machinery detects a diversity of DNA lesions and inhibits the cell cycle progression if these lesions are not repairable. DDR is involved in aging, age-related diseases, and cancer. In recent years, DDR inhibitors have gained the attention of researches due to their potentials in offering novel therapeutic targets and improving the response of many cancers to either chemo- or radio-therapy. In this regard, we tried to gather a great body of evidence about the role of DDR ingredients in osteosarcoma's initiation/progression, prognosis, and treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
22. The role of DNA damage response in chemo- and radio-resistance of cancer cells: Can DDR inhibitors sole the problem?
- Author
-
Sadoughi, Fatemeh, Mirsafaei, Liaosadat, Dana, Parisa Maleki, Hallajzadeh, Jamal, Asemi, Zatollah, Mansournia, Mohammad Ali, Montazer, Majid, Hosseinpour, Mohammad, and Yousefi, Bahman
- Subjects
- *
DNA repair , *DNA damage , *CANCER cells , *CELL cycle , *CANCER treatment , *RADIOTHERAPY - Abstract
Up to now, many improvements have been made in providing more therapeutic strategies for cancer patients. The lack of susceptibility to common therapies like chemo- and radio-therapy is one of the reasons why we need more methods in the field of cancer therapy. DNA damage response (DDR) is a set of mechanisms which identifies DNA lesions and triggers the repair process for restoring DNA after causing an arrest in the cell cycle. The ability of DDR in maintaining the genome stability and integrity can be favorable to cancerous cells which are exposed to radiation therapy or are treated with chemotherapeutic agents. When DDR mechanisms are error-free in cancer cells, they can escape the expected cellular death and display resistance to treatment. In this regard, targeting different components of DDR can help to increase the susceptibility of advanced tumors to chemo- and radio-therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
23. Targeting PI3K/Akt/mTOR signaling pathway by polyphenols: Implication for cancer therapy.
- Author
-
Mirza-Aghazadeh-Attari, Mohammad, Ekrami, Elyad Mohammadi, Aghdas, Seyyed Ali Mousavi, Mihanfar, Ainaz, Hallaj, Shahin, Yousefi, Bahman, Safa, Amin, and Majidinia, Maryam
- Subjects
- *
CANCER treatment , *HEALING , *CELL growth , *POLYPHENOLS , *CANCER invasiveness , *BERRIES - Abstract
Cancer is one of the biggest challenges facing medicine and its cure is regarded to be the Holy Grail of medicine. Therapy in cancer is consisted as various artificial cytotoxic agents and radiotherapy, and recently immunotherapy. Recently much attention has been directed to the use of natural occurring agents in cancer therapy. One of the main group of agents utilized in this regard is polyphenols which are found abundantly in berries, fruits and vegetables. Polyphenols show to exert direct and indirect effects in progression of cancer, angiogenesis, proliferation and enhancing resistance to treatment. One of the cellular pathways commonly affected by polyphenols is PI3K/Akt/mTOR pathway, which has far ranging effects on multiple key aspects of cellular growth, metabolism and death. In this review article, evidence regarding the biology of polyphenols in cancer via PI3K/Akt/mTOR pathway is discussed and their application on cancer pathophysiology in various types of human malignancies is shown. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
24. Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer.
- Author
-
Karpisheh, Vahid, Nikkhoo, Afshin, Hojjat-Farsangi, Mohammad, Namdar, Afshin, Azizi, Gholamreza, Ghalamfarsa, Ghasem, Sabz, Gholamabas, Yousefi, Mehdi, Yousefi, Bahman, and Jadidi-Niaragh, Farhad
- Subjects
- *
COLON cancer , *DINOPROSTONE , *DRUG resistance in cancer cells , *CANCER treatment , *INFLAMMATORY mediators - Abstract
• Colon cancer in one of the main health-related problems which is incurable particularly in advanced stages. • Prostanoids and particularly prostaglandin E2 (PGE2) are important inflammatory lipid mediators. • PGE2 plays an important role in tumorigenesis process of colon cancer. • PGE2 can be considered as potent therapeutic target for colon cancer therapy. Although colon cancer is one of the most important triggers of cancer related mortality, a few therapeutic options exist for this disease, including combination chemotherapy, anti-EGFR and anti-angiogenic agents. However, none of these therapeutics are fully effective for complete remission, and this issue needs further investigations, particularly in the patients with advanced disease. It has been shown that colon carcinogenesis process is associated with upregulation of prostaglandin (PG) levels. Moreover, conversion of pre-malignant cells to malignant was also related with increased generation of PGs in susceptible subjects. Among the prostanoids, PGE2 is the most important produced member which generated in high levels by colon tumor cells. Generation of PGE2 by action of cyclooxygenase (COX)-2 can promote growth and development, resistance to apoptosis, proliferation, invasion and metastasis, angiogenesis and drug resistance in colon cancer. Increased levels of PGE2 and COX-2 in colon cancer is reported by various investigators which was associated with disease progression. It is suggested that there is a positive feedback loop between COX-2 and PGE2, in which function of COX-2 induces generation of PGE2, and upregulation of PGE2 increases the expression of COX-2 in colon cancer. Although an existence of this feedback loop is well-documented, its precise mechanism, signaling pathways, and the particular E-type prostanoid (EP) receptor mediating this feedback are elusive. Therefore, it seems that targeting COX-2/PGE2/EP receptors may be supposed as a potent therapeutic strategy for treatment of colon cancer. In this review, we try to clarify the role of PGE2 in cancer progression and its targeting for treatment of colon cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.